Emergent BioSolutions Announces Sale of Travel Health Business to Bavarian Nordic for Up To $380 Million Feb 15, 2023 02:00AM
Bavarian Nordic Announces the Sale of Priority Review Voucher Dec 17, 2019 01:36PM
Vaccine Regimen from Janssen and Bavarian Nordic to Support Republic of Rwanda’s Preparedness Against Ebola Outbreak Dec 9, 2019 01:00AM
Phase 3 Results of Bavarian Nordic’s Smallpox Vaccine Published in The New England Journal of Medicine Nov 14, 2019 02:23AM
Bavarian Nordic Completes Enrollment of Phase 3 Lot-Consistency Trial of Freeze-dried Smallpox Vaccine Nov 11, 2019 01:30AM


Nov 7, 2019 06:03AM Bavarian Nordic Announces Submission of European Marketing Authorisation Applications for Investigational Ebola Vaccine Regimen
Nov 6, 2019 05:33AM Recent Advances in Bavarian Nordic’s Cancer Immunotherapy Platform Published in Nature Communications
Oct 31, 2019 08:24AM Investigational Ebola Vaccine from Janssen and Bavarian Nordic to Support Outbreak Response in Democratic Republic of the Congo
Oct 21, 2019 02:59AM Bavarian Nordic Announces a Transformative Acquisition of Two Established Commercial Vaccines from GlaxoSmithKline
Oct 8, 2019 02:44AM Bavarian Nordic Announces Initiation of Phase 1 Clinical Trial of Equine Encephalitis Virus Vaccine
Oct 3, 2019 02:09AM Bavarian Nordic Completes Enrollment of Phase 2 Trial in Chordoma Patients
Sep 24, 2019 01:45PM Bavarian Nordic Announces U.S. FDA Approval of JYNNEOS™ (Smallpox and Monkeypox Vaccine, Live, Non-replicating) for Prevention of Smallpox and Monkeypox Disease in Adults
Jun 25, 2019 02:46AM Bavarian Nordic Applauds Reauthorization of Key U.S. Biodefense Programs
Jun 5, 2019 03:11PM Bavarian Nordic Reports Positive Result from ongoing Phase 2 Trial Evaluating BN-Brachyury in Chordoma
Mar 21, 2019 05:09AM Bavarian Nordic Announces Annual Report 2018
Sep 14, 2015 04:07PM Bavarian Nordic Receives Contract Valued at USD 9 Million from Janssen as part of Advanced Development of Prime-Boost Ebola Vaccine Regimen
Aug 18, 2015 10:09AM Bavarian Nordic Initiates Phase 1 Clinical Trial of MVA-BN(r) in Respiratory Syncitial Virus (RSV)
Jul 15, 2015 02:10AM Bavarian Nordic Announces that the Oxford Vaccines Group has Initiated a Phase 2 Study of the Ebola Prime-Boost Vaccine Regimen Combining MVA-BN(r) Filo and Janssen's AdVac(r) Technology
May 13, 2015 01:36AM Bavarian Nordic Announces Positive Results from Two Pivotal Clinical Studies of IMVAMUNE(r) Smallpox Vaccine
May 12, 2015 02:04PM Bavarian Nordic Announces Presentation of Preliminary Phase 1 Results for the Ebola Prime-Boost Vaccine Regimen of MVA-BN(r) Filo and Janssen's AdVac(r) technology